FRS2 Antibody [Unconjugated]

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

FRS2 (FGFR substrate 2; also known as SNT and FRS2-alpha ) is a 70‑90 kDa member of the FRS family of lipid-anchored docking proteins. It is an intermediary between FGF and TRK receptors and their Ras/MAPK signaling cascades. Human FRS2 is 512 amino acids (aa) in length. It contains a membrane-anchoring myristoylation signal (aa 1‑6), a PTB domain that interacts with FGF and NGF receptors (aa 13‑115), and a C-terminal Tyr-rich region that serves as a docking site for Grb2 and Shp2 (aa 196‑471). One splice form shows a deletion of the C-terminal four amino acids. Over aa 121‑449, human FRS2 is 99% and 94% aa identical to canine and mouse FRS2, respectively.

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

We have publications tested in 1 confirmed species: Human.

We have publications tested in 1 application: Western Blot.

Showing Publications 1 - 3 of 3.

Publications using AF4069	Applications	Species
In Vitro and In Vivo Activity of Lucitanib in FGFR1/2 Amplified or Mutated Cancer Models Neoplasia, 2016-12-15;19(1):35-42. 2016-12-15 [PMID: 27988457] (Western Blot, Human)	Western Blot	Human
Kenshi Higashi, Yoshihisa Yamada, Shingo Minatoguchi, Shinya Baba, Masamitsu Iwasa, Hiromitsu Kanamori et al. MicroRNA-145 repairs infarcted myocardium by accelerating cardiomyocyte autophagy American Journal of Physiology-Heart and Circulatory Physiology 2015-12-01 [PMID: 26432843]
Osamu Tohyama, Junji Matsui, Kotaro Kodama, Naoko Hata-Sugi, Takayuki Kimura, Kiyoshi Okamoto et al. Antitumor Activity of Lenvatinib (E7080): An Angiogenesis Inhibitor That Targets Multiple Receptor Tyrosine Kinases in Preclinical Human Thyroid Cancer Models Journal of Thyroid Research 2014-09-10 [PMID: 25295214]

Array AF4069

• FRS2 Antibodies
• FRS2 Lysates
• FRS2 Proteins